2-[3-(3-fluorobenzyloxy)benzylamino]acetamide | 1166822-44-1

• 英文名称: 2-[3-(3-fluorobenzyloxy)benzylamino]acetamide
• 英文别名: 2-[[3-[(3-Fluorophenyl)methoxy]phenyl]methylamino]acetamide
• CAS: 1166822-44-1
• 化学式: C₁₆H₁₇FN₂O₂
• 分子量: 288.322
• InChiKey: AITHIICHOXQJIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Izzo Emanuela

  公开号：US20110014304A1

  公开（公告）日：2011-01-20

  The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.

  本公开涉及药物治疗精神障碍，其中包括精神分裂症和/或焦虑症，其中精神分裂症包括与之相关的疾病，如短暂性精神病性障碍、妄想性障碍、情感性精神病性障碍和分裂症样障碍，而焦虑症包括惊恐障碍、强迫症、创伤后应激障碍、社交恐惧症或社交焦虑症、特定恐惧症和广泛性焦虑症。本公开的化合物可用于治疗上述精神障碍，单独使用或与其他治疗精神分裂症和/或焦虑症有效的治疗剂联合使用。
• ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP2222290B1

  公开（公告）日：2021-06-16
• US8445539B2
  申请人：——

  公开号：US8445539B2

  公开（公告）日：2013-05-21
• [EN] ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS ALPHA-AMINOAMIDES UTILISÉS DANS LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES
  申请人：NEWRON PHARM SPA

  公开号：WO2009080470A1

  公开（公告）日：2009-07-02

  The present invention relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety wherein schizophrenia includes schizophrenia related disorder such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the invention are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.